Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program
{{output}}
Background: Dalfampridine extended-release tablets (dalfampridine-ER; in Europe, prolonged-release fampridine, and elsewhere, fampridine modified or fampridine sustained release), 10 mg twice daily, are available for the treatmen... ...
